The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Performance outperformance was driven by underlying business strength, favorable claims experience, and nonrecurring investment income of approximately $1 per share.

Management realigned leadership to strengthen coordination between health benefits and Carelon, aiming to bring decision-making closer to operational execution.

The company is embedding AI across clinical and administrative workflows and expects the technology to reduce prior authorization denials by nearly 70% by improving data sharing and accuracy.

Medicare Advantage repositioning remains on track to achieve at least a 2% operating margin in 2026 through disciplined product exits and pricing.

Medicaid performance benefited from targeted interventions in behavioral health and specialty pharmacy, specifically addressing rapid growth in ABA therapy.

Commercial results reflect a disciplined pricing approach and strong demand for integrated medical and pharmacy capabilities, leading to almost record pipeline levels for 2027.

Management reaffirmed confidence in delivering at least 12% adjusted EPS growth in 2027, calculated from a revised 2026 baseline of $25.75.

The 2027 growth framework assumes the maturation of current investments in AI and the realization of returns from 2025-2026 pricing and portfolio actions.

Medicaid margins are expected to trough in 2026, with 2027 benefiting from better rate alignment as states incorporate recent high-acuity experience.

Individual ACA membership is projected to end the second quarter with approximately 1.2 million members, though full-year outlook remains at at least 900,000.

Capital deployment remains focused on share repurchases, with a target of at least $2.3 billion for the full year 2026.

Recorded a $935 million accrual related to historical CMS risk adjustment data disputes; management believes this appropriately reflects potential exposure.

A $129 million business optimization charge was taken to simplify organizational structures and accelerate decision-making processes.

Recognized approximately $1 per share from nonrecurring valuation adjustments within net investment income during the first quarter.

Management noted that while CMS funding for 2027 addressed some challenges, they will remain disciplined in bid submissions to prioritize long-term value.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Employers are increasingly focused on affordability and simplicity, leading to a record pipeline for the 2027 national account season.

There is a continued trend of clients consolidating multiple carriers under a single carrier to reduce complexity and cost.

Current rate increases are near the mid-single-digit range, which remains slightly below the elevated trend observed in the business.

Management is engaging in constructive discussions with states to close the rate-to-trend gap, with July rate cycles currently under review.

A pronounced shift toward bronze plans is driving seasonality where a greater portion of planned costs are deferred to the second half of the year.

The shift is attributed to benchmark silver plan premiums rising, making bronze options more affordable on a net-of-subsidy basis.

Elevance has until July 31 to meet compliance requirements and expects that completing these steps will prevent sanctions from going into effect.

The matter is historical and does not impact current risk adjustment practices, compliance governance, or the 2026 financial outlook.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.